<div id="readability-page-1"><div>ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2025, Anika issued a press release announcing topline results from its clinical trial of Hyalofast, “a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair.” The press release stated that “[w] hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis.” On this news, the price of Anika shares declined by $3.06 per share, or approximately 27.42%, to close at $8.10 per share on July 30, 2025. What Should I Do? If you purchased or otherwise acquired Anika securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost. [LEARN MORE ABOUT SECURITIES CLASS ACTIONS] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMzA1NDkxMjFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMzA1NDkxMjFyMQ"/> Kirby McInerney LLP Lauren Molinaro, Esq. 212-699-1171 https://www.kmllp.com https://securitiesleadplaintiff.com/ investigations@kmllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20251230549121/en/</div></div>

阿尼卡医疗

Kirby McInerney LLP 正在调查 Anika Therapeutics, Inc.（纳斯达克代码：ANIK）是否违反联邦证券法，此次调查是基于 2025 年 7 月 30 日关于 Hyalofast 临床试验结果的新闻稿。该试验未能达到其主要终点，导致 Anika 股价下跌 27.42%。购买了 Anika 证券的投资者被鼓励联系该律师事务所，以获取有关其权利和调查的更多信息

阿尼卡调查：投资者被鼓励联系 Kirby McInerney LLP